Podcasts about Bayer

A special thank you to PaleoLady for our new theme music! Toay we talk about some naughty naughty Nazi collaborating corporations, among other things...If you want to listen ad-free, check out our substack at hemisphericpress.substack.com. If you'd like to publish a book with us, please email hemisphericpress@gmail.com or submit a sample chapter to editor@hemisphericpress.com

EASY LISTENING DEP'T.: It's one thing to ruin the lives of civil servants, it's quite another to inconvenience Bayer. Please visit, read, and support INDIGNITY! https://www.indignity.net/

Letzte Woche war es noch das große Rätsel, wer in Leverkusen übernimmt. Calli ließ sich nicht so wirklich locken. Jetzt ist der Däne aus dem Sack - und Calli verrät seinen Podcast-Freunden, dass er noch einen anderen Favoriten hatte. Matze ist zunächst mal skeptisch, ob das jetzt so passt, wie man sich das Bayer vorstellt. Für große Unterhaltung hat mal wieder Uli Hoeneß im Kult-Jubiläums-Doppelpass gesorgt. Auch wenn nicht alle happy waren mit seinem Auftritt. Sonntag, am Tag nach Bayern - HSV, ist ein besonderer TV-Abend für Calli. "Echte Champions XXL" ist eine Produktion der Podcastbande. Neue Folgen immer donnerstags - überall, wo es Podcasts gibt.

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Ihr Lieben!Wir sind zurück! Neue Folge neues Glück, dieser Podcast ist zurück!Dickes Bussi, Spätitourtickets gibt es noch hier:https://rausgegangen.de/events/berlins-beste-spatitour-1/

Da platzt eine Breaking News direkt in den BOHNDESLIGA-freien Montag rein! KASPER HJULMAND wird neuer Trainer von BAYER LEVERKUSEN. Das kommt durchaus überraschend, schließlich hat Hjulmand seit über zehn Jahren nicht mehr in der BUNDESLIGA gearbeitet. Wie ist dieser Transfer zu bewerten? Die BOHNDESLIGA-Crew aus Nils, Etienne, Tobi und Niko bewerten den Wechsel. Tobi erläutert, wie Hjulmand als dänischer Nationaltrainer hat spielen lassen. Etienne wirft ein paar andere Trainerkandidaten in den Raum, während Niko die kreative LEVERKUSENer Führung lobt. Wird Hjulmand die WERKSELF in die gelobte CHAMPIONS LEAGUE führen? Bleibt er länger im Sattel als Erik ten Hag? Diese und viele andere Fragen beantworten wir im BOHNDESLIGA-Special!

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

L'émission qui dit tout haut ce que le monde du foot pense tout bas ! L'« After Foot », de 20h à minuit, émission de foot la plus puissante en France, entame sa 19e saison ! Cette année, c'est Nicolas Jamain qui pilote les premières parties de soirées : « Génération After » les soirs sans matchs, de 20h à 22h, émission composée de chroniqueurs qui ont grandi avec l'After. Avec Kevin Diaz, Walid Acherchour, Jennifer Mendelewitsch, Damien Perquis, Simon Dutin, Jimmy Braun et Sofiane Zouaoui. Au programme, des débats passionnés, de nombreux invités. "After Live" les soirs de matchs, de 20h à 23h. Venez vibrer sur les soirées de coupes d'Europe, Ligue 1, Ligue 2, Equipe de France et Coupe de France. Jérôme Rothen, Emmanuel Petit et Lionel Charbonnier viennent renforcer le dispositif les soirs de Ligue des Champions, Europa League et Europa Conférence League. En deuxième partie de soirée, de 22h (ou 23h) à minuit, place à la version originelle et historique de l'After autour de Gilbert Brisbois, Daniel Riolo et Florent Gautreau. Cette année encore, Thibaut Giangrande pilote l'After Foot le samedi soir. A ses côtés, Walid Acherchour, Kévin Diaz et Damien Perquis. Le dimanche, Jean-Louis Tourre prend les commandes en direct du stade de l'affiche principale de la journée de Ligue 1 avec Kévin Diaz. Cette saison est aussi l'éclosion de la libre-antenne de l'After : Plus d'une cinquantaine de dates autour des meilleurs matchs de la saison, pour venir débattre avec Nicolas Vilas et Thibaut Giangrande à partir de minuit. Rendez-vous au 3216, surs les réseaux sociaux ou le chat Youtube pour participer à l'émission.

Meet Mina Hoshizawa, a dynamic in-house legal counsel who has built her career on adaptability and genuine connection. Now leading legal and compliance functions at Nihon Servier, she shares candid insights about unlearning perfectionism, embracing vulnerability as a leadership strength, and why being fluid like water has been her career superpower. If you are considering the transition to an in-house position or thinking you might skip the law firm experience and focus on in-house, this is the episode for you. If you enjoyed this episode and it inspired you in some way, we'd love to hear about it and know your biggest takeaway. Head over to Apple Podcasts to leave a review and we'd love it if you would leave us a message here!In this episode you'll hear:Why even practical motivations can lead to passionate careersThe art of "unlearning" from private practice what lawyers must focus on to win at in-house roles Her vulnerable leadership approach and what she often says to her teamPractical strategies for establishing legal functions from zero Where to look for opportunities if you intend to skip the law firm experienceAbout MinaMina Hoshizawa is Head of Legal and Compliance at Servier in Japan, sitting on the Leadership Team. Before joining Servier, she belonged to Bayer in Japan and served as Compliance Manager for the entire company and as Legal Manager for its Consumer Health Business and Crop Science Business. Mina is a qualified Japanese bengoshi (attorney), and before joining Bayer, she worked at Freshfields' Tokyo office. She is the leader of a working group of the Governance and Legal Committee of The European Federation of Pharmaceutical Industries and Associations (EFPIA). She was selected as LexisNexis® UNDER 40 2024, Japan Rising Star 2024 by GC Powerlist Legal 500, and became the first JILA In-house award winner in the Compliance category in Individual Awards 2023.In her free time Mina likes to play badminton with her daughter. Connect with Mina LinkedIn: https://www.linkedin.com/in/mina-hoshizawa-76ab01262/ Connect with Catherine LinkedIn https://www.linkedin.com/in/oconnellcatherine/Instagram: https://www.instagram.com/lawyeronair

Wir begrüßen euch zur letzten Sendung vor unserem Live-Podcast. Wieder einmal ist die Stimmung der drei Plattbarden hervorragend. Markus hat seinem Schuhregal einige neue Exemplare gegönnt. Ralf hat in Bayer neue Wortkreationen kennengelernt und Marco hat mit seinem Männerchor das Publikum auf dem Meppener Kleinstadtfestival begeistert. Begeisterung lösen in dieser Sendung auch die von Platti Ralf gespendeten Biere aus. Das Eibinger Edel weiß durch eine schöne Süffigkeit zu überzeugen. Das Meckatzer Löwen-Pils punktet mit würzigen Hopfennoten. Das Echte Märzen von Schwabenbräu aus Stuttgart gewinnt als letzter Tropfen den Tagessieg. Heute sprechen wir über das Thema Geschwindigkeitsübertretung im Verkehr und dessen Folgen. In der Rubrik "Dät platt Wort" geht es um das Thema Ehebruch. Ihr seht, wieder einmal viel los auf dem platten Land!

See omnystudio.com/listener for privacy information.

This week's agriculture news highlights policy developments as Congress returns to session, including updates on labor, environmental regulations and water policy. We also bring insights from Bayer Crop Science on the future of short corn. A federal district court in Louisiana recently vacated part of the 2023 Adverse Effect Wage Rate Rule, specifically the H-2A disaggregation provision. Meanwhile, the Environmental Protection Agency has withdrawn proposed revisions to wastewater regulations for meat and poultry processors. Looking ahead, the Trump administration is preparing to propose a new Clean Water Act rule in the coming weeks. Additional reports point to a projected increase in U.S. net farm income in 2025, along with new insights on ag export trends. A conversation on the future of short corn, in addition to what it provides to growers, is this week's interview with two voices from Bayer Crop Science: NA Technical Product Lead for Preceon™ Devin Hammer and Digital Enablement Product Lead Andy Folta. They share how shorter, thicker stalks benefit the plant, the length of time Bayer has been testing the Preceon™ Smart Corn System, and how short corn can also be utilized for silage. This discussion took place at the recent Farm Progress Show with Ag News Daily Co-Host Tanner Winterhof. Stay connected with us for more agriculture content on Instagram, TikTok, Facebook, and YouTube, along with our weekly videos! ALWAYS READ AND FOLLOW IRM, WHERE APPLICABLE, GRAIN MARKETING AND ALL OTHER STEWARDSHIP PRACTICES AND PESTICIDE LABEL DIRECTIONS. ©2025 Bayer Group. All rights reserved.

As if anyone cares on todays show we talk about Monsanto, Roundup, GMOs, Agent Orange, carcinogen, Bayer acquisition, lawsuits, non-Hodgkin lymphoma, seed patents, crop drift, government agencies, chemical herbicides, organic farming, Monsanto strategy, legal battles., Roundup, chemical alternatives, Epsom salts, FDA approved, natural methods, leukemia, paint stores, weed eater, garden implements, ALAR, coffee, PJs coffee, Second Round Bakery, podcast, Washington DC.

The planet Jupiter will slide past one of the brighter stars of Gemini the next few mornings. At their closest, they’ll be separated by just a fraction of a degree. The star is Wasat – from an Arabic phrase that means “the middle.” But the middle of what has been lost over the centuries. The star also is known as Delta Geminorum – its Bayer designation. The system was devised in the early 17th century by German astronomer Johann Bayer. He named all of the stars in the constellations that were visible from the northern hemisphere. Each star was given a Greek letter followed by the constellation name. If he ran out of letters, he switched to the Latin alphabet. In most constellations, Bayer named the stars in the order of their brightness. The brightest was alpha, the next-brightest was beta, and so on. Sometimes, he ranked the stars on their location or some other system. And he named the stars based on how they looked to the naked eye, so the rankings were completely subjective. So even though delta is the fourth letter in the Greek alphabet, Delta Geminorum is only the eighth-brightest star in Gemini. Jupiter and Wasat are well up in the east at dawn. Jupiter looks like a brilliant star, far to the upper right of even-brighter Venus. Wasat will stand below Jupiter tomorrow. Jupiter will drop past it over the following couple of days, so they’ll be at their closest on Saturday and Sunday. Script by Damond Benningfield

Love In Fiction. Emo hyme conductor, sunshine post-pop visionary and silver balloon gift-giver, Phil Bayer, is our guest on Episode 354 of Sappenin' Podcast! The FLOYA vocalist exclusively reveals secrets on the bands newly embraced live reputation, getting a second chance to pursue music and the heartwarming storyboard leading to their double collaboration with Grumble Bee and Airports. In this conversation, Bayer opens up on evolving from the metalcore scene to capturing summer dopamine audio, turning writing trips into exotic creative adventures, establishing unexpected German cult followings in Japan, Australia and Europe, why he almost stepped away from the industry all together, privately auditioning for Marvs ex-band ALAZKA, ego-shattering reviews vs finding his voice, laugh out loud tour memes, awkward venues, Radar Festival reviews, new music plans, hearing the taste of ejaculation and more! Turn it up and join Sean and Morgan to find out Sappenin' this week!Follow us on Social Media:Twitter: @sappeninpodInstagram: @sappeninpodSpecial thank you to our Sappenin' Podcast Patreons:Join the Sappenin' Podcast Community: Patreon.com/Sappenin.Kylie Wheeler, Janelle Caston, Paul Hirschfield, Tony Michael, Scarlet Charlton, Dilly Grimwood, Mitch Perry, Nathan Crawshaw, Molly Molloy, James Bowerbank, Amee Louise, Kat Bessant, Kieran Lewis, Alexandra Pemblington, Jonathan Gutierrez, Jenni Robinson, Stuart McNaught, Jenni Munster, Louis Cook, Carl Pendlebury, James Mcnaught, Martina McManus, Jason Heredia, John&Emma, Danny Eaton, RahRah James, Sian Foynes, Evan, Ollie Amesbury, Dan Peregreen, Emily Perry, Kalila Keane, Adam Parslow, Josh Crisp, Vicki Henshaw, Laura Russell, Fraser Cummings, Sophie Ansell, Kyle Smith, Connor Lewins, Billy Hunter, Harry Radford, George Evans, Em Evans Roberts, Thomas O'Neill, Sinead O'Halloran, Kael Braham, Jade Austin, Charlie Wood, Aurora Winchester, Jordan Harris, James Page, Georgie Hopkinson, Helen Anyetta, John Wilson, Lisa Sullivan, Ayla Emo, Kelly Young, Jennifer Dean, Tj Ambler-Shattock, Chaz Howkins, Michael Snowden, Justine Baddeley, David Winchurch, Jim Farrell, Scott Evans, Andrew Simpson, Shaun Croucher, Lewis Sluman, Ellie Gowers, Luke Wardle, Grazyna McGroarty, Nathan Matheson, Matt Roberts, Joshua Lewis, Erin Howard,, Chris Harris, Lucy Neill, Amy Thomas, Jessie Hellier, Stevie Burke, Robert Pike, Anthony Matthews, Samantha Neville, Sarah Maher, Owen Davies, Bethan Downing, Jessica Tiernan, Danielle Oldershaw, Samantha Bowen, Ruby Price, Jule Ferl, Alice Wood, Billy Parmiter, Emma Musgrave, Rhian Friggens, Hannah Kenyon, Patrick Floyd, Hayley Taylor, Loz Sanchez, Cerys Andrews, Dan Johnson, Eva B, Emma Barber, Helen Macbeth, Melissa Mercury, Joshua Ryan, Cate Stevenson, Emily Moorhouse, Jacob Turner, Madeleine Inez, Robert Byrne, Christopher Goldring, Chris Lincoln, Beth Gayler, Lesley Dargie-Walker, Sabina Grosch, Tom Hylands, Andrew Keech, Kerry Beckett, Leanne Gerrard, Ieuan Wheeler, Hannah Rachael, Gemma Graham, Andy Wastell, Jay Smith, Nuala Clark, Liam Connolly, Lavender Martin, Lloyd Pinder, Ghostly Grimoire, Amy Hogg.Diolch and Thank You x Hosted on Acast. See acast.com/privacy for more information.

Am Deadline Day hat Bayer 04 Leverkusen Erik ten Hag nach nur 2 Bundesliga-Spielen als Trainer entlassen. In der neuen Ausgabe „DONE DEALS – der Transfermarkt-Podcast“ sprechen die Hosts Fabian Knottnerus und Lennart Gens über die Gründe für das Aus, Statements dazu und die gehandelten Nachfolger auf den Trainerposten. In den Medien wird bereits viel spekuliert: Raúl, Xavi, Marco Rose, Roger Schmidt oder Ange Postecoglou – wer passt am besten zur „Werkself“? Wir bringen auch drei weitere Kandidaten ins Gespräch, die unserer Meinung als neuer Trainer infrage kommen könnten. Hier findet ihr alle aktuell vereinslosen Trainer: https://tm.de/s/Jw45

TT: The Companies That Own it All: Part 2 In this show, the teenagers (Deven and Ethan) talk about how most of the news networks, defense manufacturers, and more are owned by BlackRock, Vanguard, and State Street. As well as how BlackRock, Vanguard, and State Street own large shares in Bayer, as well as most of the other large companies that are well known and very powerful. How much power do these 3 companies (BlackRock, Vanguard, and State Street) have? This is part 2 in the series of The Companies that own it all. Sponsors: American Gold Exchange Our dealer for precious metals & the exclusive dealer of Real Power Family silver rounds (which we finally got in!!!). Get your first, or next bullion order from American Gold Exchange like we do. Tell them the Real Power Family sent you! Click on this link to get a FREE Starters Guide. Abolish Property Taxes in Ohio: https://reformpropertytax.com/ Our Links: www.RealPowerFamily.com Info@ClearSkyTrainer.com 833-Be-Do-Have (833-233-6428)

Nyle Bayer, CMO of Future Proof, joins The Advisor Journey to share how he helped turn a bold idea into one of the most innovative events in wealth management. Drawing from his background as an advisor and now event builder, Nyle explains the principles behind Future Proof's growth, from creating unforgettable experiences to engineering meaningful networking opportunities.He breaks down what advisors can learn from world-class event marketing—why product quality comes first, how every touchpoint shapes client experience, and why brand design communicates trust before you ever say a word. Nyle also discusses hiring lessons, the future of community-driven growth, and why AI represents both a reset and the biggest opportunity advisors have ever faced.This episode gives advisors a rare inside look at the mindset, playbook, and practical steps behind building movements that scale far beyond a single event.ABOUT ALTRUIST: We're on a mission to make independent financial advice better, more affordable, and accessible to everyone. As a modern custodian, Altruist helps high-growth, client-centric, and tech-forward RIAs deliver great advice to more clients at lower costs. Want to find out how Altruist can help you grow? Talk to our team by visiting www.altruist.com/talk-to-us STAY CONNECTED: Instagram ► https://www.instagram.com/altruistcorp/ Twitter ► https://x.com/altruist Linkedin ► https://www.linkedin.com/company/altruistcorp/ ABOUT THE ADVISOR JOURNEY: Real-life strategies for the modern financial advisor who's ready to scale. Join Altruist leaders and guests as they share proven tactics, unfiltered advice, and hard-won lessons you can apply to your own practice. These conversations will propel your career to the next level—don't miss it. Disclaimer: Altruist Corp ("Altruist") offers technology and tools designed to help financial advisors achieve better outcomes. Advisory and certain other services are provided by Altruist LLC, an SEC-registered investment adviser, and brokerage related products and services are provided by Altruist Financial LLC, a member of FINRA/SI...

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über Aktien mit Achterbahn-Potenzial, die nächste BYD-Schlappe und das Ende der Stada-Hoffnungen. Außerdem geht es um Rheinmetall, Renk, Hensoldt, Sartorius, Commerzbank, E.on, Siemens Energy, Bayer, TeamViewer, Strategy, Ceconomy, JD.com, The Walt Disney Company, Six Flags Entertainment, Cedar Fair Entertainment Company, United Parks & Resorts, Mitsui Fudōsan, iShares STOXX Europe 600 Travel & Leisure (A0H08S). Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Working Forward, Amy Bayer shares her personal journey through burnout, career reinvention, and the slow, intentional process of rediscovering purpose. From leading global employer brand initiatives to stepping away in search of alignment, Amy offers a vulnerable look at what it means to listen to your body, trust your instincts, and let go of what no longer serves you. She and Brent discuss how strengths like Empathy and Connectedness guided her path, the power of sabbaticals, and the questions that helped her begin again — on her terms.   Additional Resources: Connect with Amy on LinkedIn: https://www.linkedin.com/in/amy-bayer-812ba8104/ Join the PFN Community: https://community.peopleforwardnetwork.com/sign_up?request_host=community.peopleforwardnetwork.com&user%5Binvitation_token%5D=43bbc5f192b8ac515b0c44bdfac7951d8cc7fc72-4b4aa546-ba57-4904-b9fb-2ced53e9af12#email Watch the Working Forward Podcast on YouTube: http://www.youtube.com/@Jason.Cochran Connect with Jason on LinkedIn: https://www.linkedin.com/in/jason-d-cochran/ Follow PeopleForward Network on LinkedIn: https://www.linkedin.com/company/peopleforward-network/posts/?feedView=all Learn more about PeopleForward Network: https://peopleforwardnetwork.com/ Key Takeaways: - Burnout often begins when we ignore our body's quiet signals in pursuit of productivity. - Sabbaticals aren't escapes — they're opportunities to reflect, heal, and realign. - Letting go of identity tied to work is one of the hardest and most liberating parts of growth. - Strengths like Empathy and Connectedness can serve as both compass and anchor in transition. - Working forward means redefining success on your own terms — slowly, intentionally, and honestly.

Bremen - Spektakulärer Deadline Day beim SV Werder Bremen: Victor Boniface wechselt auf Leihbasis von Bayer 04 Leverkusen an die Weser und der Transfer von Cameron Puertas wurde reichtzeitig fix gemacht. Zudem wurden Leistungsträger wie Romano Schmid und Jens Stage in der abgelaufenen Transferphase nicht verkauft und Samuel Mbangula, Maximilian Wöber, Isaac Schmidt Yukinari Sugawara sowie Ersatztorwart Karl Hein verpflichtet. Die DeichStube-Podcast-Show eingeDEICHt geht in der neuen Folge in die Analyse: Wie Werder jetzt aufgestellt ist – das Transfer-Fazit. In der Werder-Podcast-Show eingeDEICHt (bei YouTube und überall, wo es Podcasts gibt) quatscht Host Timo Strömer in Folge 71 mit DeichStube-Chefreporter Daniel Cottäus natürlich über den SV Werder Bremen und insbesondere über den Wechsel von Victor Boniface. Der 40-Millionen-Euro-Stürmer ist eine Top-Verpflichtung – wenn er fit bleibt. Über die „Wette“ Boniface und alle weiteren Neuzugänge wird in eingeDEICHt Folge 71 ausführlich gesprochen. Welche Note gebt Ihr der Transferphase von Werder-Sportchef Clemens Fritz? Schreibt es gerne in die Kommentare. In der Werder-Podcast-Show eingeDEICHt, gesendet aus dem DeichStube-Office, erwartet Euch wie immer eine Vollgas-Veranstaltung vollgestopft mit den Themen, die die Fans des SV Werder Bremen beschäftigen. Und sonst? Alberne Einspieler, allerlei Blödsinn, schlechte Wortwitze, dumme Sprüche, manchmal Werder-Expertise. Cheers und viel Spaß mit eingeDEICHt – Eurem Lieblings-Podcast/Vodcast rund um den SV Werder Bremen!

Eine Pressemitteilung für die Bundesligageschichte: Nach nur zwei Spieltagen beziehungsweise 180 Minuten feuert Bayer Leverkusen seinen Trainer

Welcome back to The Bundesliga Show! In this episode, the lads take you through the huge breaking news as Erik Ten Hag was sacked by Bayer Leverkusen, plus a full transfer deadline day round up and all the key games that took place over Matchday 2 of the 2025/26 season! Hamburg kicked off the weekend on Friday evening with a derby against rivals FC St. Pauli. The away side were the better side in a 2-0 win, continuing their strong start to the season. On Saturday, Werder Bremen came back from 3-1 down with 10 men as they notched a famous point at the Weserstadion. The result has led to the sensational sacking of manager Erik ten Haag after just two games. There were wins for an impressive Eintracht Frankfurt side and Bayern Munich, who won the Bavarian Derby 3-2 in Augsburg. On Sunday, FC Koeln once again stole the show, with a hugely impressive 4-1 win over SC Freiburg. The home fans were bouncing as Bundesliga football returned the the German party city. In addition Borussia Dortmund cruised past 1. FC Union Berlin thanks to more goalscoring expolits from Serhou Guirassy.Today the key matches include:Hamburger SV vs FC St. PauliSV Werder Bremen vs Bayer 04 Leverkusen 1. FC Koeln vs SC FreiburgFC Augsburg vs FC Bayern MuenchenWhich was your favourite match of the week?Which players did you enjoy the most over this match day?Which team will be the most disappointed with their result? #bundesliga #germanfootballclub #tenhag #leverkusen #deadlineday

À quelques heures du départ de l'UTMB, RMC Running vous plonge dans les coulisses de la préparation avec un épisode Hors-Série, enregistré depuis Chamonix ! Autour de Yohan Durand, deux invités d'exception : Mathieu Blanchard, traileur de renommée mondiale qui cette année n'enfilera pas ses chaussures pour gravir la montagne mais pour encourager les copains, et Ambrine Fourari Margotin, experte santé et medical advisor chez Bayer pour la marque Berocca.Comment bien préparer une épreuve aussi exigeante que l'UTMB ? Quelle stratégie adopter pour gérer son effort sur près de 170 km ? Et surtout, comment optimiser sa récupération pour tenir jusqu'au bout ? Un échange passionnant, entre l'expérience terrain de Mathieu et l'expertise médicale d'Ambrine. Épisode exclusif à écouter juste avant le départ de la grande aventure UTMB 2025 qui s'annonce mythique !

https://www.youtube.com/watch?v=F6vA9ensrzw Podcast audio: In this episode of The Ayn Rand Institute Podcast, Ben Bayer and Nikos Sotirakopoulos critique a recent Wall Street Journal article that tries to explain Zohran Mamdani's rise and the persistence of socialism in American politics. Among the topics covered: Why socialism is not an innate impulse or the product of ignorance of history; Why idealism alone does not explain socialism's popularity; How miseducation about capitalism contributes to the endurance of socialism; Why you can't fight woke ideology while upholding Christianity's altruistic ethic; How to defeat socialism. Recommended in this podcast are Ayn Rand's Atlas Shrugged, her article “Faith and Force: The Destroyers of the Modern World,” the Ayn Rand Lexicon entry on Socialism, and Bayer's articles “The Dishonesty of ‘Real Socialism Has Never Been Tried'” and “The Old Morality of the New Religions.” The podcast was recorded on August 25, 2025 and posted on August 28, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.

Fran Maier assesses the situation on mental health, Andrea Picotti Bayer on TX and LA not understanding the Ten Commandments and Dr. Larry Chapp covers the red-pilled church.

As combines roll out across the Prairies, harvest management becomes a key focus for farmers looking to protect grain quality while maximizing efficiency. In this Wheat School episode, Rory Cranston, technical strategy lead with Bayer, speaks with RealAgriculture’s Amber Bell about tactics to help growers get into the field sooner and protect returns. One of... Read More

TT The Companies That Own it All: Part 1 In this show, the teenagers (Deven and Ethan) talk about how most of the large companies such as Hershey's, Kellogg's, Coca-Cola, and many more, are owned by one company. In this show, you will learn how most of the things that you eat, drink, and use in your everyday life are owned by Bayer. As well as how BlackRock, Vanguard, and State Street own large shares in Bayer, as well as most of the other large companies that are well known and very powerful. How much power do these 3 companies (BlackRock, Vanguard, and State Street) have? You will find out more in the part 2 of this show, coming next week. Sponsors: American Gold Exchange Our dealer for precious metals & the exclusive dealer of Real Power Family silver rounds (which we finally got in!!!). Get your first, or next bullion order from American Gold Exchange like we do. Tell them the Real Power Family sent you! Click on this link to get a FREE Starters Guide. Abolish Property Taxes in Ohio: https://reformpropertytax.com/ Our Links: www.RealPowerFamily.com Info@ClearSkyTrainer.com 833-Be-Do-Have (833-233-6428)

This week onThe Feds, we are joined by Meryl Nass, MD, founder and president of Door to Freedom, medical advisor to Children's Health Defense, and host on CHD TV. Dr. Nass provides an in-depth analysis of two concerning provisions in the 2025 House Appropriations Bill: Sections 453 and 507.  Section 453 prohibits funding for timely updates to product labels and safety recommendations, a critical issue given that successful lawsuits against chemical giant Bayer have often relied on labeling disputes. Dr. Nass explains the far-reaching implications of this rider for public health and safety. Additionally, Dr. Nass examines Section 507, which restricts government funding for the implementation or further study of a January 2025 EPA report. This report documented the toxic and carcinogenic effects of "forever chemicals" found in sewer sludge used as agricultural fertilizer, raising serious environmental and health concerns. Who in Congress is writing and supporting these sections? Why? What can YOU do as an American citizen? Tune in for this compelling discussion on critical policy issues impacting public safety and environmental health. This is an episode you won't want to miss! —Watch Dr. Nass' show regarding Section 507 (starts @ 36:30):https://live.childrenshealthdefense.org/chd-tv/shows/good-morning-chd/youre-employer-can-mandate-killing-you-poisoning-farmland/ Learn more about the history behind Section 453:https://merylnass.substack.com/p/will-congress-give-the-pesticide Read more about Section 507 and “forever chemicals:” https://merylnass.substack.com/p/sewer-sludge-was-deodorized-and-magically Dr. Nass' Organization:DoortoFreedom.org

Alexander Nübel war der entscheidende Mann bei Stuttgarts Zittersieg im Elfmeterschießen gegen Braunschweig. Bayer Leverkusen treibt den Kader-Umbruch weiter voran und der BVB verlängert mit Chefcoach Niko Kovač.

Die Bayern starten mit einem 6:0 gegen Leipzig - droht wieder Langeweile im Meisterrennen? Der Kader ist stark, aber schmal: Welche Ausfälle könnten entscheidend werden, und warum leiht der Rekordmeister derzeit nur? Bayern-Experte Mario Krischel ordnet ein. Zudem: Robert Arndt berichtet zur Basketball-EM, Niko Kovac verlängert und Bayer holt einen Ex-Real-Star.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Sentera: https://sentera.com/Chandler Coop: https://www.chandlercoop.com/Today's episode is another installment in our Tech-Enabled Advisor series. The idea here is to better understand agtech through the lens of the BUYER and USER of that technology rather than just the entrepreneurs or investors behind it. I've received some super positive feedback about the return of this series. By talking to the buyers rather than the sellers of the tech, we got an unfiltered introduction to the technology and more importantly got to see HOW its used and the VALUE that it provides. To do this, I partner with a company and together we invite one of their customers onto the show. The catch is that they're not allowed to script these individuals or dictate what to say or edit it after it is recorded - it has to be real and unfiltered. So today's episode featuring Nick Einck of Chandler Coop is produced in partnership with Sentera. Sentera is a leading provider of remote imagery solutions. Their industry-leading cameras are compatible with most major drone platforms and enable farmers and crop scouts to efficiently capture high-resolution data. Their capabilities and FieldAgent software tools help farmers and agronomists assess plant-level health, identify stressors, and take action. Also their customized herbicide prescription, SMARTSCRIPT™ Weeds, can be delivered to sprayers with individual nozzle control.So drones equipped with Sentera technology fly over fields at high speeds and generate high-resolution images. The images are processed using proprietary deep learning algorithms to identify the exact location of specific weeds and generate a weed map. This map becomes a targeted prescription for how much product a farmer needs to load into their sprayer, saving money and minimizing waste. This past May, John Deere announced they were acquiring Sentera.So I'm very excited to partner with them for this episode, which is a fantastic deep dive into how innovative technology like this combined with something like See-and-Spray really changes the game.Some background on Nick before we dive in: Nick Einck is the Director of Agronomy at Chandler Co-op, a farmer-owned cooperative serving more than 900 customers and providing agronomic services across over 100,000 acres in southwest Minnesota. He began his career at Chandler as an intern and seed manager before spending nearly a decade with Monsanto and Bayer, gaining deep expertise in agronomy, product development, and grower engagement across the Midwest. Nick returned to Chandler in October 2024, bringing both retail and industry experience to help advance the co-op's agronomic strategy. Today, he leads a multi-location agronomy team focused on leveraging tech-enabled tools—like SmartScript™—to help growers make faster, more informed decisions and drive greater return from every acre.

Para Maurício Rodrigues, CEO da Divisão Agrícola da Bayer para a América Latina, a agricultura precisa ser parte da solução, atuando para minimizar os impactos. Era do Clima: Rumo à COP-30 é apresentado por Ambipar, BNDES, Governo Federal, Governo do Pará, Hydro e JBS.See omnystudio.com/listener for privacy information.

Der erste Bundesliga-Samstag liegt hinter uns und hatte einige Überraschungen parat. Dortmund verzockt eine 3:1-Führung gegen St. Pauli. Can Uzun zaubert beim Eintrachts Kantersieg gegen Werder und Stuttgart und Leverkusen verpatzen den Auftakt.

Bayer schießt Leipzig ab und macht dem Rest der Liga schon wieder Angst! Beim HSV gibt es eine überraschende Torwart-Entscheidung und Gio Reyna steht vor einem Wechsel nach Gladbach.

“Savings is completely self-invented and pointless because it's separated from the real P&L." This assessment from Bayer Chief Procurement Officer Thomas Udesen captures the essence of what may be procurement's most radical transformation in decades. In this episode of “Buy: The Way...To Purposeful Procurement,” Thomas joins Philip Ideson and Rich Ham to discuss how one of the world's largest pharmaceutical companies abandoned traditional procurement metrics entirely, replacing “savings” with six C's that actually drive business outcomes: cost, cash, carbon, community, compliance, and continuity.  Thomas's approach defies conventional wisdom at every turn.  At Bayer, every employee can spend up to €50,000 without pre-approval – a level of transactional autonomy that would terrify most procurement organizations. Yet the results speak for themselves: increased responsibility, entrepreneurial thinking, and more strategic spend management decisions driven by transparency rather than control. The conversation reveals how procurement's obsession with “savings” has become a self-inflicted wound. Stakeholders roll their eyes when procurement leads with savings slides because the metrics mean nothing to them. Instead, Bayer measures real P&L impact through price index benchmarking and spend ratios that directly correlate to competitive performance.  In this episode, Thomas demonstrates that purposeful procurement isn't just theoretical; it's already happening. His parting challenge: procurement can be “the heartbeat of the change that is coming.”    Links: Thomas Udesen on LinkedIn Rich Ham on LinkedIn Learn more at FineTuneUs.com

Sermon delivered on the Feast of the Assumption of the Blessed Virgin Mary, 2025, in Richmond, Texas, by Rev. Tobias Bayer. Epistle: Eccl. 29, 11-13. Gospel: St. Luke 10, 38-42.

Sermon delivered on the Tenth Sunday After Pentecost, 2025, in Richmond, Texas, by Rev. Tobias Bayer. Epistle: 1 Cor. 12, 2-11. Gospel: St. Luke 18, 9-14.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über ein Dekadenhoch in China, zwei frohe Botschaften bei Novo Nordisk und Rückenwind bei Windkraftaktien. Außerdem geht es um Rheinmetall, Hensoldt, Renk, Leonardo, Thales, Shanghai Composite, CSI 300, Tencent Music, Nio, Netease, Xiaomi, Tencent, Alibaba, BYD, JD, Vestas, Energiekontor, Siemens Energy, Nordex, SMA Solar, Bayer, GoodRX, Duolingo, Pro7Sat.1, Intel, Nvidia, Home Depot, Starbucks, Netlfix, Sixt, CTS Eventim, Nike, Spotify, Live Nation Entertainment, AMC, Amazon, Kyivstar, VEON. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of One Dream, Leah Wilson and Bernadette Pajer dive deep into the urgent conversation about pesticides, food reform, and the corporations shaping our agricultural future. From Bayer and Monsanto's political influence to the hidden dangers in our food system, they unpack how liability shields, weak EPA oversight, and gaps in transparency put public health at risk. The discussion covers the health impacts of pesticide exposure—including cancer and reproductive issues—and reveals how consumer choice and political engagement can drive meaningful reform. Listeners will learn why regenerative agriculture offers hope, how to demand transparency in labeling, and why protecting our right to hold pesticide companies accountable is non-negotiable. This is more than a conversation—it's a rallying call for informed citizens to stand up for food safety, environmental health, and the future of farming. What You'll Learn in This Episode: How Bayer and Monsanto shape laws to protect the pesticide industry Why the term “pesticide” covers far more than herbicides The EPA's regulatory blind spots and their consequences Health risks tied to pesticide exposure How consumer awareness can change agricultural practices Why transparency in food labeling matters How political reform can protect public health and the environment The promise of regenerative agriculture as an alternative Why we must fight against pesticide liability shields Resources Mentioned: Find all of Stand for Health Freedom's resources on the pesticide issue, here. One Dream on Instagram: @onedream.podcast — DM us your detox questions Follow The One Dream Podcast:

Sermon delivered on the Feast of St. Lawrence, 2025, and the Ninth Sunday After Pentecost, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: 2 Cor. 9, 6-10. Gospel: St. John 12, 24-26.

https://www.youtube.com/watch?v=Gm7PICSLkhc Podcast audio: In this episode of The Ayn Rand Institute Podcast, Ben Bayer and Agustina Vergara Cid take a wide-ranging look at abortion bans since the overturning of Roe v. Wade, examining their destructive effects on the lives and freedoms of women and medical professionals. Among the topics covered: Ayn Rand's distinctive defense of abortion rights; How abortion bans have impaired women's lives; How anti-abortion laws impose arbitrary constraints against sound medical judgment; The unfortunate rise of pregnancy-related prosecutions; How abortion restrictions jeopardize doctors' freedom and careers; Why signs of resistance show abortion bans can be reversed; Evidence that the anti-abortion movement is motivated by a dark anti-sex agenda. Recommended in this podcast are the Ayn Rand Lexicon entry on Abortion, Bayer's book “Why the Right to Abortion Is Sacrosanct,” and his article “The Dark Form of Control Even Anti-Abortion ‘Moderates' Want.” The podcast was recorded on July 28, 2025 and posted on August 9, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.

Tom Preston, co-author of COACHING POWER, is the founder of The Preston Associates, one of the world's premier executive coaching firms. With decades of experience coaching leaders across industries and geographies, he has helped organizations achieve extraordinary outcomes. A former private equity executive and bestselling author of Coach Yourself to Success, he brings deep insights and practical wisdom to his work.Luciana Nuñez, co-author of COACHING POWER, is an accomplished executive coach and former CEO with more than 20 years of leadership experience at Fortune 500 companies, including Bayer, Danone, and Roche. She blends her strategic expertise with a passion for mentoring, serving as a board member, investor, and advisor to entrepreneurs and executives worldwide.

Dr. Hoffman continues his conversation with Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community.” 

Zen Honeycutt, founder and executive director of Moms Across America and author of “Unstoppable: Transforming Sickness and Struggle into Triumph, Empowerment and a Celebration of Community,” details the origins and mission of the nonprofit organization aimed at transforming the food supply and improving health by reducing chemicals in food, water, and air. Highlighting the impact of grassroots activism, Honeycutt illustrates how the organization's initiatives have driven significant awareness and policy changes, including advances in organic food consumption and labeling. She also touches on the challenges posed by government and corporate influences, advocating for policies that put children's health and safety first. Honeycutt emphasizes the importance of individual actions and community involvement in creating a healthier future.

This new chemical immunity bill pretends to support farmers while legally granting immunity from lawsuits against harm to the producers of pesticides, herbicides, fungicides, and insecticides. There have been billions of dollars in settlements from glyphosate, and there are currently 165,000 active cancer lawsuits against the producer. If this immunity bill passes, all of these lawsuits will go away!Section 453 of the bill grants legal immunity to domestic and foreign chemical producers. Future failure-to-warn pesticide lawsuits would be dismissed. We often trust chemicals and drugs that are considered safe and effective, only to find out that they are actually deadly. This is due to a loophole allowing drug and chemical companies to keep negative safety studies confidential and unpublished. The Modern Ag Alliance is a “front group” created by Bayer. They create grassroots movements to make it appear that most people agree that glyphosate is a critical farming tool. They claim that it's safe and vital to secure our food supply. Groups within the WHO have labeled glyphosate as a probable carcinogen for humans, and many people have won cancer lawsuits against the manufacturer. Despite the evidence, chemical companies are taking a food security stance, claiming we will starve without glyphosate.Kelly Ryerson explains that if these companies achieve legal immunity, they will be allowed to continue to use chemicals that have been shown to cause health problems like Parkinson's, cancer, ALS, infertility, and more, with no consequences! This agricultural chemical liability shield will be virtually impossible to reverse if passed.To fight back against the pesticide legal immunity bill, contact your state senators and tell them you do not support any language granting legal immunity to chemical companies!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.